Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

These ratings communicate expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

Why Moderna stock fell. Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine developer's artificial intelligence ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where ranks on the list. With the 2024 US ...

Moderna (MRNA-0.39%) has posted major gains for two straight years. In 2020, investors bet on the biotech company's ability to bring a coronavirus vaccine to market, and they won. Moderna scored ...

We expect the Covid-19 shot to remain the primary driver of Moderna’s performance in 2022 as well. The global inoculation drive is still in the early stages, with the Bloomberg Vaccine Tracker ...